Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAS123 vs Aripiprazole in the Maintenance Treatment of Schizophrenia
NCT07843056Phase 2Completed
- Sponsor
- EMS
- Start
- May 2022
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by EMS. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started May 2022; status: completed.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07843056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843056.